CUPERTINO, CA - (NewMediaWire) - March 12, 2019 - Aemetis, Inc. (NASDAQ: AMTX) announced that the company will host a conference call to review the release of its fourth quarter and year-end 2018 earnings report:Date: Thursday, March 14, 2019Time: 11 am Pacific Time (PT)Live Participant Dial In (Toll Free): +1(877) 407-8035Live Participant Dial In (International): +1(201) 689-8035Webcast URL: http://www.investorcalendar.com/event/45300Attendees may submit questions during the Q&A portion of the conference call.After March 14th, the webcast will be available on the Company’s website (www.aemetis.com) under Investors/Conference Calls. The voice recording will also be available through March 21, 2019 by dialing (Toll Free) (877) 481-4010 or (International) +1 (919) 882-2331 and entering conference ID number 45300.About AemetisHeadquartered in Cupertino, California, Aemetis is an advanced renewable fuels and biochemicals company focused on the acquisition, development and commercialization of innovative technologies that replace traditional petroleum-based products by the conversion of ethanol and biodiesel plants into advanced biorefineries. Founded in 2006, Aemetis owns and operates a 60 million gallon per year ethanol production facility in California’s Central Valley, near Modesto. Aemetis also owns and operates a 50 million gallon per year renewable chemical and advanced fuel production facility on the East Coast of India producing high quality distilled biodiesel and refined glycerin for customers in India, the US and Europe. Aemetis operates a research and development laboratory, and holds a portfolio of patents and related technology licenses for the production of renewable fuels and biochemicals. For additional information about Aemetis, please visit www.aemetis.com.External Investor Relations Contact: Kirin Smith PCG Advisory Group (646) 863-6519 ksmith@pcgadvisory.com Investor Relations/ Media Contact: Todd Waltz (408) 213-0940 investors@aemetis.com
Prodrug of THC Improves Fluid Outflow Across Trabecular Meshwork and Positively Impacts Disease Markers Associated with Glaucoma-Related Fibrosis and InflammationChanges in Neovascularization Markers Indicate Potential Utility of NB1111 in Diabetic Retinopathy and Macular Degeneration Long Beach, CA - (NewMediaWire) - March 12, 2019 - Nemus Bioscience, Inc. (OTCQB: NMUS), a biopharmaceutical company focused on developing bioengineered cannabinoid-based therapeutics to address global medical indications, announced today that data generated by Glauconix Biosciences, Inc. has validated the mechanism of action of NB1111, Nemus’ proprietary prodrug of tetrahydrocannabinol (THC-valine-hemisuccinate, or THCVHS), in lowering intraocular pressure (IOP), a defining symptom of hypertensive glaucoma.The analyses involved a laboratory model using human donor cells that contained the ocular tissue responsible for helping to regulate intraocular pressure, the trabecular meshwork. The studies included a comparison of the activity of tetrahydrocannabinol (THC), the biologically active part of NB1111, in facilitating fluid drainage resulting in lower IOP as well as lowering levels of biomarker molecules associated with inflammation and fibrosis, two processes associated with tissues that are damaged in a disease setting – including glaucoma and other ocular disordersResearchers have previously demonstrated that ocular tissues possess a high degree of cannabinoid receptors, especially on organs that help regulate IOP. Given that THC binds both types of cannabinoid receptors, these data point to a unique mechanism of action whereby the ability of THC to bind to cannabinoid receptors results in a beneficial decline in IOP due to enhanced fluid drainage. When IOP is left unchecked, there is often damage to the optic nerve, leading to irreversible vision loss. Additionally, biomarkers associated with inflammation and fibrosis in tissues affected by glaucoma were significantly decreased, pointing to anti-inflammatory and anti-fibrotic activities that are often associated with the cannabinoid class of molecules in other disease-states. The studies also demonstrated that two biomarkers associated with neovascularization, a process of new blood vessel formation that can lead to vision loss or retinal detachment, were significantly lowered by exposure to THC. Neovascularization is often associated with diabetic retinopathy and macular degeneration, two leading causes of blindness, especially in older adults. “The Glauconix Biosciences’ 3D-HTM™ technology was designed to help accelerate drug development by using bioengineered human donor 3D tissue models for target identification and validation, high throughput screening, and drug efficacy with physiological endpoints, such as fluid outflow,” commented Karen Torrejon, Ph.D., Founder and Chief Scientific Officer of Glauconix. “Historically, our technology has exhibited significant predictive value in assessing a drug candidate’s utility and likelihood of clinical success. Nemus’ data helps to provide a rationale for cannabinoid activity in lowering IOP and indicates a potential for the advancement of NB1111 into clinical testing.” “These studies were significant across a spectrum of findings and we plan on submitting the data to an upcoming major ophthalmology meeting. Micro-quantities of cannabinoid delivered directly into the eye could have the dual benefit of a therapeutic effect while mitigating risk of systemic adverse events through direct tissue targeting, an advantage associated with using bioengineered molecules,” remarked Brian Murphy, MD, CEO and Chief Medical Officer of Nemus. “The impact on markers of ocular neovascularization also reinforces our commitment to test our cannabinoid-based ocular platform of NB1111, the prodrug of THC, and NB2222, the analog of cannabidiol (CBD), in ocular indications beyond glaucoma.”About Glauconix BiosciencesGlauconix Biosciences is a leading developer of ophthalmic ex-vivo dynamic 3D human tissue models for accelerating therapeutic innovation and ...
Seattle, WA - (NewMediaWire) - March 12, 2019 - CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing FluroTech Ltd. (TSX-V: TEST) (OTCQB: FLURF). The company recently announced a new proof-of-concept for its advanced cannabis biomarker technology, which enables cultivators, dispensaries, and regulators to easily trace products across the supply chain.The cannabis industry is projected to exceed $146 billion by 2025, according to Grand View Research, driven by the legalization of adult-use and medical cannabis around the world. With the breakneck pace, the industry has faced a number of growing pains along the way. Product recalls, counterfeit products, mislabeled products, and supply chain issues have introduced challenges for growers, dispensaries, consumers, and regulators.Supply Chain ChallengesThe cannabis industry has experienced rapid growth over the past several years, but there have been plenty of growing pains along the way. According to one study, 35 percent of more than 80 cultivars tested had genetics that didn’t match the cultivar being sold. Consumers were buying Sativa cultivars that were advertised as Indica and vice versa. California cannabis labs are also finding toxic metals in vape cartridges, which could cause serious health issues.Counterfeit products have caused other problems. G Pen, a leading high-end portable vaporizer, was awarded $47 million in 2017 after suing more than 60 online retailers selling counterfeit versions of their products. Even worse, some dispensaries were found to be selling fake vape cartridges, which could introduce health risks since the contents of those cartridges are completely unknown and unregulated.“Legal cannabis markets around the world continue to express concern about black market production entering regulated systems,” says FluroTech CEO Danny Dalla-Longa. “Regulators, responsible for consumer protection, have noted an increase in the number of these allegations. Legal growers need to protect their brands and reputation, which we believe creates an expanding market for our technology.”Governments have also struggled to control the supply chain. Without a good way to track legal product, there’s no way for them to ensure that legal cannabis remains out of the black market and black market cannabis remains out of the legal market. Tracking solutions could also enable them to trace cannabis back to its origins for tax collection purposes, as well as to assist with any product recalls that may be issued.Please Click Here to Receive a FluroTech Investor Presentation and Future Updates.Biomarker-based SolutionsDNA biomarkers, short for biological markers, have become a popular way to track everything from clothing to livestock. After applying a spray solution, the DNA acts as a molecule-sized encrypted barcode that can be used to track almost anything across a supply chain. The fashion industry, for example, has used the technology to verify the authenticity of high-end clothing and accessories to combat counterfeit products.The same technology can be applied to the cannabis industry. By bonding to the plant, biomarker technologies can withstand processing and even show up in refined products, such as oils and edibles. Dispensaries, regulators, cultivators and other interested parties can feed the product into a reader to access the unique “encrypted barcode”. This information can be used to confirm the origin, strain, permit or other relevant information.While most conventional biomarking technologies utilize sprays, FluroTech’s CTO Dr. Elmar Prenner doesn’t believe that these will be acceptable under future Health Canada regulations. The company recently announced a proof-of-concept technique that introduces water-based biomarkers through the root system of cannabis and hemp plants, so that the nanoparticles are absorbed throughout all of the plant.Using the company’s cost-effective CompleTest™ equipped with biomarking scopes, these unique ...
NexTech’s AR Dispensary will enable consumers to preview cannabis products such as flowers, gear, pre-rolls and more from home; platform utilizes immersive AR and 3D photography to educate consumers before the purchasing decisionNew York - (NewMediaWire) - March 12, 2019 - NexTech AR Solutions (the “Company” or “NexTech”) (OTC: NEXCF)(CSE: NTAR)(FSE:N29) today announced the launch of its innovative augmented reality (“AR”) platform for the legal cannabis industry, AR Dispensary.To experience the AR Dispensary, please click here.NexTech’s AR Dispensary utilizes immersive AR technology and rich 3D 360-degree photography to provide an eCommerce experience like no other in the legal cannabis industry. The white-label web-based AR solution, integrated into a dispensary’s website seamlessly through just a snippet of code, enables consumers to preview products like flowers, gear, pre-rolls, and more from home or on-the-go. The platform can also support features for online ordering/pickup, and online ordering/delivery (where permitted), creating a complete digital dispensary experience.“As an end-to-end eCommerce and education solution for the legal cannabis industry, AR Dispensary provides dispensary owners with a comprehensive solution that is scalable, customizable and, most importantly, easy to integrate within an existing web interface,” said Evan Gappelberg, CEO of NexTech. “Whether a dispensary’s goal is to educate customers on potential health benefits of cannabis or simply to increase sales, AR Dispensary provides the interactive online experience consumers crave that drives brand loyalty and awareness.”Traditionally the education process for cannabis consumers takes place at the dispensary, through a conversation with the “Budtender.” This can be both time-consuming and confusing for the customer, especially if they are new to the industry. Instead, with AR Dispensary, legal cannabis sellers can empower consumers to educate themselves before entering the dispensary, ensuring they have the knowledge to make an informed purchasing decision. “When people are planning to make a purchase both in-store and online, many are using the internet to research products to ensure they’re making the right purchasing decision. We do it with clothes, electronics, and other consumer goods – why should cannabis be any different?” Gappelberg said. “AR Dispensary provides that traditional research and purchase experience for dispensaries that we’ve seen be so successful across a host of other industries. This is truly a next-generation experience that will drive engagement and learning within the cannabis industry.” With spending on legal cannabis worldwide expected to reach $57 billion by 2027, according to Arcview Market Research and BDS Analytics, on-demand, interactive AR experiences are the next step towards improving customers’ path to purchase. The release of AR Dispensary continues NexTech’s penetration into the burgeoning market, following its deal with Cannvas Medtech Inc., a leading digital cannabis education and business technology company, in January 2019.About NexTech AR Solutions Corp.NexTech is bringing a next generation web enabled augmented reality (AR) platform with Artificial Intelligence (AI) and analytics to the Cannabis industry, eCommerce, education, training, healthcare and video conferencing. Having integrated with Shopify, Magento and Wordpress its technology offers eCommerce sites a universal 3D shopping solution. With just a few lines of embed code, the company’s patent-pending platform offers the most technologically advanced 3D-AR, AI technology anywhere. Online retailers can subscribe to NexTech’s state of the art, 3D-AR/AI solution for $79/mo. The company has created the AR industry’s first end-to-end affordable, intelligent, frictionless, scalable platform. To learn more, please follow us on Twitter, YouTube, Instagram, LinkedIn, and Facebook, or visit our website: https://www.nextechar.com.On behalf of the Board of NexTech AR Solutions Corp.“Evan Gappelberg”CEO and DirectorFor further information, ...
Study Highlights: Out-of-hospital cardiac arrest was the third leading cause of “health loss due to disease” in the United States behind ischemic heart disease and low back/neck pain in 2016. Bystander interventions, such as CPR and AED application, significantly reduce death and disability due to out-of-hospital cardiac arrests. Embargoed until 4 a.m. CT / 5 a.m. ET Tuesday, March 12, 2019 (NewMediaWire) - March 12, 2019 - DALLAS - Out-of-hospital cardiac arrest was the third leading cause of “health loss due to disease” in the United States behind ischemic heart disease and low back/neck pain in 2016, according to new research in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal. This groundbreaking study is the first to estimate disability-adjusted life years (DALY) – which measures the sum of years of life lost prematurely and years lived with disability due to a disease – among those who experienced non-traumatic out-of-hospital cardiac arrest in the United States. Cardiac arrest is an abrupt loss of the heart’s ability to pump, which leads to death within minutes if not treated. Its effect on years lost to premature death and disability is currently unknown. Using the national Cardiac Arrest Registry to Enhance Survival (CARES) database, researchers examined 59,752 cases of adult, non-traumatic, Emergency Medical Services (EMS)-treated out-of-hospital cardiac arrest from 2016. Researchers found: Disability-adjusted life year rates for out-of-hospital cardiac arrest were 1,347 per 100,000 individuals, ranking it as the third leading cause of health loss due to disease in the United States behind ischemic heart disease (2,447) and low back and neck pain (1,565); Individuals who experienced out-of-hospital cardiac arrest lost an average of 20.1 healthy years; and At the national level, this resulted in 4.3 million healthy life years lost, representing 4.5 percent of total DALY in the country. Researchers also measured the effects of bystander intervention – CPR and automated external defibrillator (AED) application – on the disease burden of out-of-hospital cardiac arrest. Focusing their analysis on a subpopulation of bystander-witnessed out-of-hospital cardiac arrest events, researchers found that on a national level: Survival to hospital discharge was higher for those who received bystander CPR than for those who did not (21.5 percent vs. 12.9 percent); Bystander CPR alone was associated with 25,317 healthy life years saved; and CPR paired with AED defibrillation was associated with 35,407 healthy life years saved. Researchers noted that women tended to have higher DALY values than men, as well as Caucasians compared to African Americans. Additionally, Hispanic race was associated with higher DALY compared with Caucasians. “Many cardiac arrests occur outside of the hospital, and our results show that bystander interventions reduce death and disability, underscoring the importance of bystander CPR and AED education, as well as national cardiac arrest surveillance,” said Ryan A. Coute, D.O., lead study author and Emergency Medicine resident at the University of Alabama at Birmingham. Researchers hope that this study may help focus public health policies, resources and future research on resuscitation science. “Cardiac arrest is unique because survival is dependent on the timely response of bystanders, medical dispatch, EMS personnel, physicians and hospital staff,” Coute said. “We hope that the results of our study provide an opportunity to emphasize the fact that ‘cardiac arrest’ and ‘heart attack’ are not synonymous. Our results may also help inform funding agencies and policy makers regarding how to best utilize limited resources to improve public health.” Co-authors are Brian H. Nathanson, Ph.D., Ashish Panchal, M.D., Ph.D., Michael C. Kurz, M.D., Nathan L. Haas, M.D., Bryan McNally, M.D., Robert W. Neumar, M.D., Ph.D. and Timothy J. Mader, M.D. Author disclosures are on the manuscript. Researchers reported no source of funding and author disclosures are detailed in ...
Oakland, CA - (NewMediaWire) - March 12, 2019 - SPRV Holdings, Inc. (f.k.a Supurva Healthcare Group, Inc.) (OTC PINK: SPRV) (the "Company"), is announcing that the Board of Directors and management have consulted with legal and financial advisors and have retained an audit firm to prepare for the next phase of the Company’s growth and development. The Company has retained Fruci & Associates to conduct audits of the Company’s wholly owned operating subsidiaries, Web To Door Corp, On Courier 365, and Web To Door Trucking Corp.Web To Door Trucking Corp. was created and merged into the Company for the purposes of managing the Company’s Utah operations.About Web To Door Corp.Web To Door Corp’s wholly owned operating subsidiary, On Courier 365, provides “Last Mile Delivery” solutions to large E-Commerce customers in the San Francisco Bay area, Oakland, Sacramento and San Jose, California, and Web To Door Trucking Corp manages the Company’s Salt Lake City, Utah market. For more information please visit http://webtodoor.com/ and http://oncourier365.com/About Web To Door, Inc. (SPRV)The Company has transitioned into the logistics and logistics service sector. Web To Door, On Courier 365, and Web To Door Trucking are 100% wholly owned subsidiaries of SPRV Holdings, Inc.Safe HarborThis release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. The words "may," "would," "will," "expect," "estimate," "can," "believe," "potential" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is and will be included in the Company’s filings with the Securities and Exchange Commission.SPRV Holdings, Inc. Public Relations and Shareholder Information Corporate Communications Department Phone: (914) 361-9877 Email: info@webtodoor.com Website: www.webtodoor.com Twitter: @WebToDoor
